Checkpoint Capital L.P. Raises Holdings in Kymera Therapeutics, Inc. $KYMR

Checkpoint Capital L.P. raised its position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 76.2% during the first quarter, HoldingsChannel.com reports. The fund owned 136,605 shares of the company’s stock after buying an additional 59,070 shares during the quarter. Kymera Therapeutics accounts for about 2.1% of Checkpoint Capital L.P.’s holdings, making the stock its 9th biggest position. Checkpoint Capital L.P.’s holdings in Kymera Therapeutics were worth $3,739,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in KYMR. Wellington Management Group LLP boosted its position in shares of Kymera Therapeutics by 13.0% during the 1st quarter. Wellington Management Group LLP now owns 5,996,873 shares of the company’s stock worth $164,134,000 after purchasing an additional 689,547 shares in the last quarter. Deerfield Management Company L.P. Series C bought a new position in shares of Kymera Therapeutics during the 4th quarter worth about $23,856,000. Janus Henderson Group PLC boosted its position in shares of Kymera Therapeutics by 2,397.9% during the 4th quarter. Janus Henderson Group PLC now owns 377,384 shares of the company’s stock worth $15,197,000 after purchasing an additional 362,276 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Kymera Therapeutics by 7.0% during the 1st quarter. Vanguard Group Inc. now owns 5,231,392 shares of the company’s stock worth $143,183,000 after purchasing an additional 344,080 shares in the last quarter. Finally, Siren L.L.C. boosted its position in shares of Kymera Therapeutics by 9.1% during the 1st quarter. Siren L.L.C. now owns 3,240,313 shares of the company’s stock worth $88,687,000 after purchasing an additional 270,580 shares in the last quarter.

Analyst Ratings Changes

Several brokerages recently weighed in on KYMR. UBS Group dropped their price target on shares of Kymera Therapeutics from $72.00 to $70.00 and set a “buy” rating on the stock in a research report on Tuesday, May 13th. Bank of America raised shares of Kymera Therapeutics from a “neutral” rating to a “buy” rating and set a $51.00 price target on the stock in a research report on Monday, June 2nd. Guggenheim reaffirmed a “buy” rating and issued a $60.00 price target on shares of Kymera Therapeutics in a research report on Tuesday, June 3rd. Stifel Nicolaus began coverage on shares of Kymera Therapeutics in a research report on Tuesday, May 20th. They issued a “buy” rating and a $55.00 price target on the stock. Finally, Jefferies Financial Group set a $64.00 price target on shares of Kymera Therapeutics and gave the company a “buy” rating in a research report on Wednesday, June 25th. Three research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Buy” and an average target price of $58.76.

Insiders Place Their Bets

In related news, Director Bros. Advisors Lp Baker acquired 655,500 shares of the company’s stock in a transaction dated Monday, June 30th. The stock was bought at an average cost of $44.00 per share, with a total value of $28,842,000.00. Following the acquisition, the director owned 6,117,295 shares of the company’s stock, valued at approximately $269,160,980. The trade was a 12.00% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Bvf Partners L. P/Il acquired 317,167 shares of the company’s stock in a transaction dated Monday, June 30th. The shares were bought at an average cost of $44.00 per share, with a total value of $13,955,348.00. Following the completion of the acquisition, the director directly owned 2,798,795 shares in the company, valued at $123,146,980. The trade was a 12.78% increase in their position. The disclosure for this purchase can be found here. Insiders own 16.01% of the company’s stock.

Kymera Therapeutics Price Performance

Shares of NASDAQ:KYMR opened at $43.30 on Thursday. The firm has a fifty day moving average price of $43.46 and a two-hundred day moving average price of $36.91. Kymera Therapeutics, Inc. has a one year low of $19.44 and a one year high of $53.27. The company has a market cap of $3.10 billion, a price-to-earnings ratio of -12.48 and a beta of 2.17.

Kymera Therapeutics (NASDAQ:KYMR) last posted its quarterly earnings data on Monday, August 11th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.12). Kymera Therapeutics had a negative return on equity of 31.60% and a negative net margin of 616.03%.The company had revenue of $11.48 million for the quarter, compared to the consensus estimate of $17.37 million. During the same period in the prior year, the firm posted ($0.58) earnings per share. The business’s revenue was down 55.1% on a year-over-year basis. Equities research analysts expect that Kymera Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.